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Abstract
Background—There has been a trend toward limiting perioperative prophylactic antibiotics,
based on research not conducted in plastic surgery patients. The authors’ university hospital
instituted antibiotic prescribing guidelines based on the Surgical Care Improvement Project. An
increased rate of surgical-site infections was noted in breast reconstruction patients. The authors
sought to determine whether the change in antibiotic prophylaxis regimen affected rates of
surgical-site infections.
Methods—A retrospective study compared patients undergoing breast reconstruction who
received preoperative and postoperative prophylactic antibiotics with a group who received only a
single dose of preoperative antibiotic. Type of reconstruction and known risk factors for implant
infection were noted.
Results—Two hundred fifty patients were included: 116 in the pre–Surgical Care Improvement
Project group and 134 in the Surgical Care Improvement Project group. The overall rate of
surgical-site infections increased from 18.1 percent to 34.3 percent (p = 0.004). Infections
requiring reoperation increased from 4.3 percent to 16.4 percent (p = 0.002). Multivariate logistic
regression demonstrated that patients in the Surgical Care Improvement group were 4.74 times
more likely to develop a surgical-site infection requiring reoperation (95 percent CI, 1.69 to
13.80). Obesity, history of radiation therapy, and reconstruction with tissue expanders were
associated with increased rates of surgical-site infection requiring reoperation.
Conclusions—Withholding postoperative prophylactic antibiotics in prosthetic breast
reconstruction is associated with an increased risk of surgical-site infection, reoperation, and thus
reconstructive failure. The optimal duration of postoperative prophylactic antibiotic use is the
subject of future study.
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Surgical-site infection is a potential complication for all surgical procedures and is one of
the leading causes of morbidity for postmastectomy breast reconstruction.1–3 Surgical-site
infections have been reported in approximately 2 percent of patients undergoing
postmastectomy implant breast reconstruction.2 Although this rate has varied widely in a
number of different studies,4 it likely represents infections that required implant removal.
Infections can range from mild cellulitis requiring oral antibiotics to more severe cellulitis
resolving with inpatient intravenous antibiotics to frank abscess formation requiring implant
removal, and thus the actual rates of infection, if defined more broadly, may be much higher.
Most plastic surgeons prescribe preoperative prophylactic antibiotics for patients undergoing
breast reconstruction and continue perioperative prophylactic antibiotics administered
intravenously during hospitalization and orally on discharge until a set time (e.g., 7 days) or
until drains are removed.5 This practice has been prone to criticism by infection control
officers and others who quote data from studies6–11 suggesting that, despite the increasing
use of prophylactic antibiotics, there has been no corresponding decrease in rates of
infection postoperatively. However, Hawn and colleagues12 recently examined the efficacy
of improved adherence to the Surgical Care Improvement Project guidelines and noted
stable rates of surgical-site infection at the patient and hospital levels despite increased use
of preoperative prophylactic antibiotics and decreased use of postoperative prophylactic
antibiotics. These studies would suggest that prolonged (>24 hours) postoperative
prophylactic antibiotics are not indicated for routine clean surgical procedures.
At our university-affiliated tertiary care center, guidelines governing the use of perioperative
antibiotic prophylaxis were implemented in October of 2008 based on pay-for-performance
incentives and the Surgical Care Improvement Project. Our Division made a decision to
adopt evidence-based perioperative antibiotic prophylaxis guidelines and in January of 2009
began prescribing a single pre-operative dose for all patients undergoing breast
reconstruction. Patients undergoing lengthy operations (e.g., perforator flap) were given
additional intraoperative doses as indicated. Although the Surgical Care Improvement
Project protocol permitted up to 24 hours of postoperative antibiotics, our group made a
decision not to give any postoperative prophylactic antibiotics in an effort to engage in
strictly evidence-based medicine.
In the ensuing year, an increase in the rate of postoperative surgical-site infection was noted
in patients undergoing breast reconstruction, particularly those undergoing prosthetic
reconstruction. This prompted a review of our experience before and after the Surgical Care
Improvement Project protocol was instituted to determine whether or not the change in
perioperative antibiotic prophylaxis regimen was associated with an increased risk of
surgical-site infection. We hypothesized that patients receiving postoperative prophylactic
antibiotics would have decreased postoperative infection rates compared with patients who
received only perioperative antibiotics according to the Surgical Care Improvement Project
protocol.
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This institutional review board–approved, retrospective cohort study was conducted at a
tertiary academic medical center between October of 2007 and January of 2010. Patients
who underwent post-mastectomy breast reconstruction before implementation of the
Surgical Care Improvement Project protocol between October of 2007 and October of 2008
received both preoperative and postoperative antibiotics (until drains were removed). This
group was compared with similar patients who underwent postmastectomy implant or
autologous reconstructions performed between January of 2009 and January of 2010. These
patients received only preoperative and possibly intraoperative antibiotics in accordance
with the Surgical Care Improvement Project guidelines. We report the rates of surgical-site
infection in both groups using a much broader definition of infection than has been reported
in the plastic surgery literature, which has tended to report only the rate of infections
requiring implant removal. We categorized surgical-site infection according to the way it
was treated: infections requiring oral antibiotics only, those treated with intravenous
antibiotics, and those requiring reoperation.
Preoperative variables included demographic factors known to be associated with surgical-
site infection, including age, body mass index, current smoking status, radiation history,
chemotherapy history, tumor stage, and diabetic status. Body mass index was also
categorized (≤30 versus >30). Intra-operative variables included technical aspects of the
procedure such as single or two-stage implant reconstruction and type of autologous
reconstruction. Women undergoing single-stage reconstruction were excluded from all
analyses. Women who received tissue expanders or permanent implants were combined for
all analyses. Patients who underwent reconstruction using both an autologous flap and an
implant were included in the implant group. Postoperative infection rates are reported.
Povidone-iodine was the most commonly used preparation solution; however, chlorhexidine
was also occasionally used. Antibiotic irrigation was used at the discretion of the attending
surgeon and was not reported consistently. Non–penicillin-allergic patients all received
cefazolin preoperatively. Penicillin-allergic patients received either clindamycin or
vancomycin; however, this information was not specifically captured in our database. After
the implementation of the Surgical Care Improvement Project guidelines, we began
capturing the distribution profile of organisms isolated from women who experienced
postoperative infection. Bacterial isolates for women requiring removal of the implant are
reported.
The majority of patients undergoing breast reconstruction had mastectomy for curative
resection. Other patients underwent prophylactic mastectomy after positive genetic testing
for the BRCAI and BRCAII genes or because of a strong familial history of breast cancer. In
subset analyses, we also examined the use of AlloDerm (LifeCell Corp., Branchburg, N.J.)
and axillary lymph node dissection, either before or concurrent with the mastectomy.
Sample Size Estimation
Although the published rate of infection after implant reconstruction is approximately 2
percent, this rate likely reflects only cases requiring removal of the implant. In a pilot study
at our institution, patients undergoing implant reconstruction experienced an increase in the
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baseline infection rate from 5.4 percent to 18.2 percent with the implementation of the
Surgical Care Improvement Project protocol. This study was adequately powered to detect a
20 percent difference in the rate of infection between the two groups studied. A type I error
probability of 5 percent (alpha) and a type II error probability of 10 percent (beta) were used
for this calculation. We estimated an event rate (proportion) of 10 percent in the group
treated with preoperative antibiotics only. The required sample size in each of the two study
groups was 47 patients, or a total sample size of 94 patients.
Statistical Analyses
Descriptive statistics, including frequencies for the independent variables and unadjusted
rates of infection, are reported. Pearson’s chi-square and Fisher’s exact tests were used for
categorical variables and t tests were used for continuous independent variables.
Multivariate logistic regression using a backward, conditional modeling technique was used
to investigate predictors of surgical-site infection requiring reoperation. Values of p < 0.05
were considered statistically significant. SPSS version 19 (SPSS, Inc., Chicago, Ill.) was
used for all analyses.
RESULTS
A total of 250 women were included for analyses (116 in the pre–Surgical Care
Improvement Project group and 134 in the Surgical Care Improvement Project group). There
were no statistically significant differences in the mean age of patients, diabetic status,
current smoking status, radiation history, chemotherapy history, or tumor stage between the
two groups (Table 1). The women in the Surgical Care Improvement Project group had a
slightly higher body mass index (27.2 versus 28.8; p = 0.052). The overall rate of surgical-
site infection (treated with any modality) increased from 18.1 percent in the pre–Surgical
Care Improvement Project group to 34.3 percent after the adoption of the Surgical Care
Improvement Project treatment protocol (p = 0.004) (Table 2). No statistically significant
differences were noted in the rates of surgical-site infection successfully treated with oral or
intravenous antibiotics alone, but the rate of infection requiring reoperation increased from
4.3 percent to 16.4 percent (p = 0.002). Regarding the different types of reconstruction, the
number of tissue expander surgical-site infections increased from 18.5 percent to 34.3
percent in the pre–Surgical Care Improvement Project group versus the Surgical Care
Improvement Project group (p = 0.013). The number of tissue expanders requiring removal
increased from 5.4 percent to 18.2 percent (p = 0.007). Among women undergoing
autologous reconstruction, we did note an overall increase in surgical-site infection rates
from 16.7 percent in the pre–Surgical Care Improvement Project to 34.3 percent in the
Surgical Care Improvement Project group; however, this difference was not statistically
significant (p = 0.135). We also noted an increase in the number of autologous flap
reconstruction surgical-site infections requiring reoperation (0 percent versus 11.4 percent);
however, this difference was also not statistically significant (p = 0.115).
In multivariate analyses, after adjusting for history of radiation therapy, body mass index
(categorized as ≤30 versus >30), treatment group (pre–Surgical Care Improvement Project
versus Surgical Care Improvement Project), and type of reconstruction performed
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(autologous versus tissue expander/implant), patients in the Surgical Care Improvement
Project group were 4.74 times (95 percent confidence interval, 1.69 to 13.80) more likely to
develop a surgical-site infection requiring reoperation than patients treated in the pre–
Surgical Care Improvement Project group. Furthermore, patients with a history of radiation
therapy were 4.50 times (95 percent confidence interval, 1.80 to 11.29) more likely to
develop a surgical-site infection requiring reoperation than patients not treated with
radiation. Obese women (body mass index >30) were 4.99 times (95 percent confidence
interval, 2.03 to 12.31) more likely to develop a surgical-site infection requiring reoperation,
and women who underwent reconstruction with tissue expanders/implants were 3.77 times
(95 percent confidence interval, 1.11 to 12.83) more likely to develop a surgical-site
infection requiring reoperation and removal of the tissue expander/implant after adjusting
for the above covariates (Table 3).
In subset analyses of the women who developed a surgical-site infection requiring
reoperation (n = 27), history of axillary lymph node dissection and use of AlloDerm were
not associated with a surgical-site infection requiring reoperation (p = 0.334 and p = 0.819,
respectively). Use of AlloDerm was less common (43.8 percent) in the Surgical Care
Improvement Project group versus the pre–Surgical Care Improvement Project group (56.3
percent); however, the difference was not statistically significant (p = 0.128). We also
examined the time interval between initial surgery and the development of a surgical-site
infection requiring implant removal, and compared results between the two treatment
groups. We found that women in the pre–Surgical Care Improvement Project group
developed a surgical-site infection a mean of 256 ± 182 days after surgery compared with
women in the Surgical Care Improvement Project group, who developed a surgical-site
infection a mean of 90 ± 93 days (p = 0.011) after surgery. Regarding early infections
requiring explantation (≤30 days), fewer women in the pre–Surgical Care Improvement
Project group (20 percent) developed such an infection compared with women in the
Surgical Care Improvement Project group (35 percent) (p = 0.477). Bacterial isolates before
and after implementation of the Surgical Care Improvement Project guidelines are reported
in Figures 1 and 2. After implementation of the Surgical Care Improvement Project protocol,
the bacterial isolates became more diverse, with a much higher incidence of Gram-negative
bacteria (Fig. 2).
DISCUSSION
Women undergo mastectomies for both prophylactic and therapeutic reasons. Whether
performed to treat breast cancer or as a preventative measure for women with a genetic
predisposition to cancer or strong familial indicators, breast reconstruction following a
mastectomy can be performed by placement of an implant or by means of autologous
techniques. Surgical-site infection following breast reconstruction can necessitate oral or
intravenous antibiotic therapy, lengthen the duration of the hospital stay, or lead to loss of
the implant or flap. An evidence-based universal protocol governing the use of prophylactic
antibiotics to prevent postoperative surgical-site infections following breast reconstruction
does not currently exist.1,2
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The current standard of care is that a preoperative dose of prophylactic antibiotic should be
given to patients undergoing postmastectomy breast reconstruction.4,13 In an advisory
statement from the National Surgical Infection Prevention Project, which is based on
published evidence, infusion of the first antimicrobial dose should begin no sooner than 60
minutes before the incision.12 Based on published evidence, the same workgroup endorsed
the national performance measure (Surgical Care Improvement Project guidelines) that
prophylactic antimicrobial agents should be discontinued within 24 hours of the end of
surgery.12 However, specific recommendations for plastic surgery were not included. Many
surgeons prescribe postoperative antibiotics for up to 1 week following postmastectomy
breast reconstruction, whereas others routinely continue postoperative antibiotics until all
drains are removed, which can be as long as 2 weeks.5
According to the published Guideline for Prevention of Surgical-Site Infection,14 three
categories of variables have proven to be reliable predictors of surgical-site infection risk:
(1) those that estimate the intrinsic degree of microbial contamination of the surgical site, (2)
those that measure the duration of an operation, and (3) those that serve as markers for host
susceptibility. Patient-related factors possibly associated with an increased risk of surgical-
site infection include remote site infection or colonization, diabetes, cigarette smoking,
obesity, extremes of age, and poor nutritional and immunocompromised status.15–22 Many
of these characteristics are present in the plastic surgery patient population, including
overweight and obese patients, current smoking status and, to a lesser extent, diabetes and
immunosuppression.
There have been a number of excellent studies from the general surgery and surgical
oncology literature examining surgical-site infection rates among women undergoing
surgery for breast cancer. A review of this literature by Penel et al.23 and others have
documented surgical-site infection rates ranging from 1.9 to 50 percent.24–37 In the
prospective study by Penel et al. comparing surgical-site infection rates before and after the
implementation of prophylactic antibiotics, the authors conclude that the antibiotic
prophylaxis reduced the risk of surgical-site infection in breast cancer surgery by 81 percent.
A recent systematic review of the literature examining preoperative and perioperative
prophylactic antibiotic use in breast surgery included seven articles with a total of 1924
participants in a meta-analysis.38 No eligible studies evaluating prophylactic antibiotics used
during reconstructive surgery (with or without implants) were identified in this study. From
this review, pooling of the results demonstrated that prophylactic antibiotics significantly
reduce the incidence of surgical-site infection for patients undergoing breast cancer surgery
without reconstruction (pooled relative risk, 0.66; 95 percent confidence interval, 0.48 to
0.89). No studies presented separate data for patients who underwent reconstructive surgery
at the time of removal of the breast tumor.
Other studies have examined the overall incidence of periprosthetic infection following
tissue expander insertion for breast cancer reconstruction. In a review by Francis et al.,39 the
authors noted infection rates ranging from 2.5 to 24 percent.40–45 Other authors have
reported infection rates after expander-based reconstructions ranging between 1 and 24
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percent.41,44,46,47 However, no consensus regarding the use of postoperative antibiotics after
implant reconstruction exists.
There have been only a small number of randomized clinical trials examining antibiotic
prophylaxis following breast reconstruction. In the only prospective, double-blinded,
placebo-controlled trial of a single dose of azithromycin on postoperative wound infections
in plastic surgery patients conducted by Amland et al.,48 the authors reported significantly
fewer wound infections (5 percent versus 20 percent) in patients undergoing breast
reconstruction who received prophylactic antibiotics. There was a significant reduction in
postoperative complications with the additional use of antibiotics postoperatively in the
prophylaxis group.48
Recent findings published by the National Surgical Infection Prevention Project suggest that
the administration of prophylactic antibiotics should be discontinued within 24 hours of the
completion of surgery.2 These recommendations, however, are based on studies outside of
the practice of plastic surgery and are not based on studies conducted with women
undergoing implant-based reconstructions. Reconstructive breast surgery differs from other
types of surgery because of a greater surface area of undermined tissue, nearly universal
ischemia to the skin flaps from the mastectomy, breast duct bacteria, and the possible
presence of an implant.
We have noted an increase in the rate of surgical-site infections requiring treatment with oral
and intravenous antibiotics and a statistically significant increase in the rate of surgical-site
infection requiring reoperation since the adoption of the Surgical Care Improvement Project
guidelines at our institution. Before the adoption of the Surgical Care Improvement Project
guidelines, our rate of surgical-site infection requiring reoperation was similar (4.3 percent)
to the rates reported in the literature (approximately 2 to 15 percent); however, we currently
have an unacceptably high rate of surgical-site infection requiring reoperation (16.4
percent). In our patient population, single-dose prophylactic intravenous antibiotic use has
not been associated with a decreased risk of surgical-site infection, resulting in a greater
number of reconstructive failures in patients undergoing prosthetic breast reconstruction.
This risk is 4.74 times higher than in patients receiving postoperative prophylactic
antibiotics. We have also noted a higher proportion of Gram-negative bacteria from the
wound culture isolates of women requiring implant removal after the implementation of the
Surgical Care Improvement Project guidelines (Fig. 2). Bacterial isolates from women
treated with postoperative antibiotics who required removal of the implant before the
implementation of the Surgical Care Improvement Project guidelines were more likely to
grow Staphylococcus (Fig. 1). The use of postoperative prophylactic antibiotics in this group
may have prevented Gram-negative infections and selected for more common and/or
resistant Staphylococcus species, although we were unable to demonstrate this statistically.
We acknowledge several limitations of this study, with the foremost being its retrospective
nature. Patients were not randomized and the duration of antibiotic therapy in the pre–
Surgical Care Improvement Project group was not controlled for. Antibiotics were stopped
after drain removal, which was performed when output was less than 30 ml/day. Although
this was consistent, we did not record the mean duration of postoperative antibiotic use.
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Surgeons at our institution adopted the use of AlloDerm at approximately the same time;
however, it was not used in all implant-based reconstructions. We did not record the rate of
AlloDerm use for the entire study population, as the purpose of this study was not to
examine risk associated with this product and it was used selectively and infrequently. Our
group has been using this product for a number of years before the study and therefore we
do not feel a learning curve effect was present. We are currently undertaking a prospective
randomized study of the duration of antibiotic use at our institution and its impact on the
development of surgical-site infection in patients undergoing prosthetic breast
reconstruction. We will compare the efficacy of postoperative antibiotic prophylaxis in
patients receiving the maximum allowed by current Surgical Care Improvement Project
protocol (24 hours) to those receiving an experimental protocol (7 days).
The optimal duration of postoperative prophylactic antibiotic therapy has not been well
established in the plastic surgery literature, and we believe the current recommendations are
inadequate. We believe that a single dose of preoperative prophylactic antibiotics is not
enough and has resulted in higher rates of surgical-site infection requiring reoperation in
patients undergoing prosthetic breast reconstruction.
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Bacteria isolated before implementation of the Surgical Care Improvement Project protocol.
PO, oral; IV, intravenous; OSSA, oxacillin-sensitive Staphylococcus aureus.
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Bacteria isolated after implementation of the Surgical Care Improvement Project protocol.
PO, oral; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; ORSA,
oxacillin-resistant Staphylococcus aureus; OSSA, oxacillin-sensitive Staphylococcus aureus.
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Table 1
Patient Demographic and Clinical Characteristics
Pre-SCIP (%) SCIP (%) p
No. of patients 116 134
Mean age, yr 48.5 ± 10.1 49.5 ± 11.5 0.502
Mean BMI 27.2 ± 5.7 28.8 ± 7.2 0.052
Diabetic 4 (3.4) 7 (5.2) 0.495
Currently smoking status 17 (14.7) 14 (10.4) 0.314
Radiation therapy 32 (27.6) 46 (34.3) 0.251
Neoadjuvant chemotherapy 37 (31.9) 54 (40.3) 0.189
Concurrent chemotherapy 9 (7.7) 14 (10.4) 0.516
Adjuvant chemotherapy 3 (2.6) 5 (3.7) 0.728
Average tumor stage 1 1 0.953
SCIP, Surgical Care Improvement Project; BMI, body mass index.
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Table 2
Surgical Site Infection, by Type of Reconstruction
Pre-SCIP (%) SCIP (%) p*
No. of patients 116 134
Total patients with SSI 21 (18.1) 46 (34.3) 0.004
SSI treated with oral antibiotics 10 (8.6) 15 (11.2) 0.499
SSI treated with IV antibiotics 6 (5.2) 9 (6.7) 0.608
SSI requiring reoperation 5 (4.3) 22 (16.4) 0.002
Reconstruction with tissue expander 92 (79.3) 99 (73.9) 0.313
Infected tissue expander 17 (18.5) 34 (34.3) 0.013
Infected tissue expander requiring reoperation 5 (5.4) 18 (18.2) 0.007
Reconstruction with autologous flap 24 (20.7) 35 (26.1) 0.313
Infected autologous flap 4 (16.7) 12 (34.3) 0.135
Infected autologous flap requiring reoperation 0 (0) 4 (11.4) 0.115
SCIP, Surgical Care Improvement Project; SSI, surgical-site infection; IV, intravenous.
*
Italicized values represent significant findings.
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Table 3
Multivariate Logistic Regression Results Predicting Surgical-Site Infection Requiring Reoperation*
Adjusted Odds Ratio (95% CI) p†
Pre-SCIP group 1.00
SCIP group 4.74 (1.69–13.80) 0.004
Radiation therapy
 No 1.00
 Yes 4.50 (1.80–11.29) 0.001
Body mass index
 ≤30 1.00
 >30 4.99 (2.03–12.31) <0.001
Tissue expander/implant
 No 1.00
 Yes 3.77 (1.11–12.83) 0.033
CI, confidence interval; SCIP, Surgical Care Improvement Project.
*
N = 250 patients.
†
All p values represent significant findings.
Plast Reconstr Surg. Author manuscript; available in PMC 2014 August 24.
